{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 45,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Data shows ELVN-002 efficacy and safety profile compared to Tucatinib and Poziotinib.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/40",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Beas2b HER2 YVMA Xenograft Body Weight Change",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43467ea4-89ff-4c9d-9b48-cec32c86c0ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Beas2b HER2 YVMA Xenograft TGI",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5555f960-9b48-49aa-9e6b-f948f25d083e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "BID = Twice a day. MTD = Maximum tolerated dose. TGI = Tumor growth inhibition. QD = Once a day. Tucatinib 300 mg BID (tablet) human AUCtau ~5,234 ng*hr/mL (NDA); mouse 100 mg/kg AUC ~143,600 ng*hr/mL (internal data). Pozi 16 mg human AUC ~450 ng*hr/mL (Spectrum website); mouse 1 mg/kg AUC ~3,500 ng*hr/mL (internal data)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3192c06-c83f-4277-8a4d-40c5912ed6a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "Poziotinib's MTD in this model was 1 mg/kg, and this dose yielded an exposure ~8x its human exposure at 16 mg QD. ELVN-002 yielded deep tumor regressions, and all doses tested were well-tolerated. Minimal TGI vs. YVMA observed with tucatinib treatment up to ~14x its human exposure at 300 mg BID",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d16480d4-2b06-494f-9961-289138af4dcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ELVN-002 Demonstrated Robust Anti-Tumor Activity in Beas2b HER2 YVMA Xenograft Model at Well-Tolerated Doses",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "127e5941-5aca-4178-af81-9d064427a20d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}